

Treatt H117 results

A brilliant half

Treatt has delivered yet another strong set of results. The business continues to perform very well and the constant stream of upgrades demonstrates the strength of momentum as the company moves further up the value chain. The pipeline is looking increasingly strong and recent growth means capacity expansion costing \$11-14m is required at Treatt USA and is independent of the UK site relocation. We upgrade our FY18 and FY19 earnings estimates by c 2% and c 4%, respectively.

Year end	Revenue (£m)	PBT* (£m)	EPS* (p)	DPS (p)	P/E (x)	Yield (%)
09/16	88.0	9.6	14.3	4.4	29.3	1.0
09/17e	102.1	13.6	19.9	6.0	21.1	1.4
09/18e	109.3	14.8	21.6	6.5	19.4	1.5
09/19e	114.7	15.6	22.9	6.9	18.3	1.6

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Strategy delivering excellent results

Treatt's long-term strategy is to deliver consistent, sustainable growth in profit through developing value-added ingredient solutions, coupled with effective cost control. Improved customer focus and closer relationships are a key part of this strategy, with the ultimate goal of delivering greater profitability by concentrating on the more value-added segments. This has been delivered consistently, with results often beating expectations, and momentum is now accelerating, with more frequent and more significant upgrades coming through. As a result of the H1 results, we upgrade our forecasts for 2018-19 to reflect the improved outlook and pipeline. Our sales forecasts move up c 2-3%, while PBT and EPS increase by c 2-5%, as Treatt's move up the value chain should deliver a strong improvement in margins.

Momentum remains strong, US capacity expansion

H117 sales were 27% above those of the previous year. A stronger US dollar accounts for c 10% of this, but the remainder is due to impressive organic growth. H1 adjusted PBT was 63% higher than last year. Given the strength of the order pipeline, Treatt USA needs to expand its capacity. Management has announced it will commence work on the expansion in FY17 and it will cost \$11-14m. We have updated our forecasts to reflect a \$12m spend. The interim dividend is up 7%, and timing has been permanently brought forward to fall in H1. The ingredients space remains attractive, with higher than average growth compared to the wider consumer space. Margins are also typically high at the value-added end as these ingredients are highly specialised and deliver key attributes to the products.

Valuation: Fair value of 438p

Our DCF-derived fair value is 438p (previously 401p), c 5% upside to the current share price. The move is driven by our forecast upgrades and our increased confidence in the business given the positive momentum, which leads us to increase our medium-term sales growth assumption to 4.5% (from 3.5%).


Food & beverages

N/A

	9 May 2017
Price	420.00p
Market cap	£218m
Net debt (£m) at 31 March 2017	8.0
Shares in issue	51.9m
Free float	100%
Code	TET
Primary exchange	LSE

Share price performance

Secondary exchange



Business description

Treatt provides innovative ingredient solutions from its manufacturing bases in Europe, North America and Africa, principally for the flavours and fragrance industries and multinational consumer goods companies, with particular emphasis on the beverage sector.

Next events	
FY trading update	September 2017
FY17 results	28 November 2017
Analysts	
Sara Welford	+44 (0)20 3077 5700
Paul Hickman	+44 (0)20 3681 2501
consumer@edisonaroup.c	com

Treatt is a research client of Edison Investment Research Limited

Edison profile page



Forecast revisions

We detail our key changes to P&L forecasts in Exhibit 1 below. We have left our main FY17 forecasts unchanged following our recent upgrade in April (detailed in our <u>note</u>). Our EPS change is purely as a result of updating our model for the slightly increased number of shares in issue (the stellar business performance has clearly resulted in a number of share schemes vesting). We have upgraded our FY18 and FY19 forecasts as Treatt is accelerating its move up the value chain, and order books for FY18 are accelerating, as confirmed by the news of the US capacity expansion. We continue to see potential for further upgrades. Improved sales growth should lead to operating leverage, and the move towards value-added products should continue to be beneficial to margins.

Exhibit 1: Old vs new key P&L forecasts										
	EPS* (p)			PBT* (£000s)			Sales (£000s)			
	Old	New	% change	Old	New	% change	Old	New	% change	
2017e	18.0	18.0	-0.4%	12,560	12,560	0.0%	102,126	102,126	0.0%	
2018e	19.2	19.5	1.9%	13,353	13,660	2.3%	107,233	109,275	1.9%	
2019e	19.8	20.7	4.2%	13,816	14,456	4.6%	111,522	114,739	2.9%	

Source: Edison Investment Research. Note: *EPS and PBT are stated on a company normalised basis, which is pre-exceptional but after amortisation of acquired intangibles and share-based payments.

We assume the Treatt USA capacity expansion spend is \$12m, split evenly between FY17 and FY18. This causes an increase in our FY17 net debt forecast from £1.0m to £5.6m, and our FY18 net debt moves from £11.2m to £16.7m. We note unutilised headroom in borrowing facilities was £16.4m at 31 March 2017, and we continue to expect both the UK relocation and the US expansion projects to be debt-funded. Management, however, has not ruled out equity funding for the UK site relocation, though a decision has not yet been made.

Treatt | 9 May 2017 2



	£000s	2014	2015	2016	2017e	2018e	2019
Year end 30 September		IFRS	IFRS	IFRS	IFRS	IFRS	IFR
PROFIT & LOSS							
Revenue		79,189	85,934	88,040	102,126	109,275	114,73
Cost of Sales		(61,218)	(66,955)	(67,639)	(76,623)	(81,440)	(85,283
Gross Profit		17,971	18,979	20,401	25,503	27,835	29,45
EBITDA		9,068	10,307	11,604	15,839	17,607	18,83
Operating Profit (before amort., except and sbp.)		7,846	9,063	10,257	14,137	15,786	16,91
Intangible Amortisation		(172)	(175)	(142)	(160)	(160)	(160
Share based payments		(46)	(198)	(566)	(858)	(933)	(987
Other		0	0	0	0	0	
Operating Profit		7,628	8,690	9,549	13,119	14,693	15,77
Net Interest		(724)	(740)	(703)	(559)	(1,033)	(1,317
Exceptionals		(1,402)	(174)	(553)	0	0	45.00
Profit Before Tax (norm)		7,122	8,323	9,554	13,578	14,753	15,60
Profit Before Tax (FRS 3)		5,502	7,776	8,293	12,560	13,660	14,45
Profit Before Tax (company)		6,904	7,950	8,846	12,560	13,660	14,45
Tax		(1,553)	(1,786)	(2,144)	(3,203)	(3,483)	(3,686
Profit After Tax (norm)		5,326 3,949	6,537	7,410	10,375	11,269	11,91
Profit After Tax (FRS 3)			5,990	6,149	9,357	10,177	10,77
Average Number of Shares Outstanding (m)		51.3	51.5	51.9	52.1	52.1	52.
EPS - normalised (p)		10.4	12.7	14.3	19.9	21.6	22.
EPS - normalised & fully diluted (p)		10.3	12.6	14.1	19.4	21.1	22.
EPS - (IFRS) (p)		7.7	11.6	11.8	18.0	19.5	20.
Dividend per share (p)		3.8	4.0	4.4	6.0	6.5	6.
Gross Margin (%)		22.7	22.1	23.2	25.0	25.5	25.
EBITDA Margin (%)		11.5	12.0	13.2	15.5	16.1	16.
Operating Margin (before GW and except.) (%)		9.9	10.5	11.7	13.8	14.4	14.
BALANCE SHEET							
Fixed Assets		13,777	13,381	16,161	26,951	45,071	48,21
Intangible Assets		1,801	1,736	3,364	3,204	3,044	2,88
Tangible Assets		10,994	10,998	11,361	22,311	40,591	43,89
Investments		982	647	1,436	1,436	1,436	1,43
Current Assets		43,590	45,045	54,435	51,913	53,873	55,27
Stocks		28,020	25,799	29,990	31,214	32,306	32,77
Debtors		14,509	17,635	17,853	20,199	21,066	22,00
Cash		629	1,477	6,588	500	500	50
Other		432	134	4	0	0	
Current Liabilities		(16,005)	(13,481)	(16,388)	(20,877)	(29,461)	(27,352
Creditors		(12,729)	(12,675)	(15,834)	(16,817)	(17,995)	(18,894
Short term borrowings		(2,356)	(567)	(487)	(4,060)	(11,466)	(8,458
Provisions		(920)	(239)	(67)	0	0	
Long Term Liabilities		(12,602)	(11,760)	(17,021)	(11,342)	(14,845)	(13,141
Long term borrowings		(7,857)	(7,065)	(7,755)	(2,030)	(5,733)	(4,229
Other long term liabilities		(4,745)	(4,695)	(9,266)	(9,312)	(9,112)	(8,912
Net Assets		28,760	33,185	37,187	46,644	54,638	63,00
CASH FLOW							
Operating Cash Flow		3,528	8,667	10,804	14,736	16,625	18,12
Net Interest		(724)	(740)	(703)	(559)	(1,033)	(1,317
Tax		(1,552)	(1,469)	(2,022)	(3,203)	(3,483)	(3,686
Capex		(538)	(924)	(679)	(12,652)	(20,101)	(5,221
Acquisitions/disposals		(208)	(103)	(861)	Ó	Ó	,
Financing		105	147	280	0	0	
Dividends		(1,899)	(1,978)	(2,095)	(2,257)	(3,116)	(3,389
Net Cash Flow		(1,288)	3,600	4,724	(3,936)	(11,109)	4,51
Opening net debt/(cash)		8,294	9,584	6,155	1,654	5,590	16,69
HP finance leases initiated		0	0	0	0	0	
Other		(2)	(171)	(223)	(0)	(0)	
Closing net debt/(cash)		9,584	6,155	1,654	5,590	16,699	12,18

Treatt | 9 May 2017 3



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Treatt and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or compiledeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed as personalised advice. Also, our website and the information provided by us should not be construed as a financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with